Twelve-month real-world data demonstrated that switching from a first-generation VEGF inhibitor to brolucizumab (Beovu) achieved a clinically significant extension of the treatment interval in patients with neovascular age-related macular degeneration (nAMD).  

The retrospective analysis of Australian and Italian data from the prospective observational Fight Retinal Blindness! registry included patients who were switched to brolucizumab and received at least two injections with 12 months of follow up. 

Among the 81 eyes studied, inactive lesions increased from 5% at baseline to 37% after 12 months of brolucizumab treatment. Vision remained stable over this period. The mean time between treatments increased from 44 to 63 days. However, nearly a third (30%) of eyes switched back to another VEGF treatment within 12 months.  

At 12 months, eyes that continued to receive brolucizumab had longer gaps between treatments than those that switched (66.1 vs. 49 days), while vision outcomes and lesion control were similar. Inflammation occurred in seven treated eyes (9%).